

THE UNIVERSITY OF MICHIGAN

REGENTS COMMUNICATION

Approved by the Regents

June 19, 2008

ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and GeneVivo, LLC

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Division of Research, Development and Administration while reviewing the Proposal Approval Form. This then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed by this Board and agreed to by the parties involved.

The proposed agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Dr. Michael Welsh is an employee of the University of Michigan and partial owner and officer of GeneVivo, LLC. The law permits such an agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

Dr. Michael Welsh is a Professor of Cell and Developmental Biology, Medical School and is the partial owner and Chief Scientific Officer of a for-profit company called GeneVivo, LLC ("Company"). The Company desires to fund a project in the Medical School.

Nature of the Agreement:

The Company has applied for and received a Phase I award from the National Institutes of Health (NIH) under the Small Business Innovative Research (SBIR) Program for the purpose of developing a novel method for transgenesis of rats. The Company wishes to enter into a subcontract with the University to enable Dr. Welsh to assist in the performance of this funded research.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is ten (10) months and the amount of funding support is \$41,399.

Impact of the Agreement:

The Agreement will support an effort by Dr. Welsh to use his expertise and his University of Michigan laboratory, as well as other University resources, such as University animal facilities, to produce and test the functionality of a plasmid vector by designing and interpreting experiments to analyze vector function in cultured cells that will establish a novel method for transgenesis of rats.

Recommendation:

This Agreement has been reviewed and approved by the Medical School Conflict of Interest Board. In light of the disclosure made in this document and our finding that the agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve of the University's entering into this Agreement with GeneVivo, LLC.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Stephen Forrest", with a long horizontal flourish extending to the right.

Stephen R. Forrest
Vice President for Research

June 2008